Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
Patients with severe refractory ulcerative colitis (UC) or those who received placebo in
study F506-CL-1107 will receive tacrolimus for a maximum of 12 weeks. Safety and efficacy
will be evaluated.